Medinet Co (TSE:2370) Piotroski F-Score: 2 (As of Jul. 13, 2026) — 33% Below Median


TSE:2370 Medinet Co Ltd TSE:2370
41 GF Score
Price 円25.00
GF Value 円41.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Medinet Co Piotroski F-Score?

Medinet Co TSE:2370 41 Piotroski F-Score is 2 as of Jul. 13, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates TSE:2370 with a GF Score™ of 41/100 and a GF Value™ of 円41.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,333 Biotechnology companies, Medinet Co ranks worse than 72.92% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Medinet Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Medinet Co's Piotroski F-Score or its related term are showing as below:

TSE:2370' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 6
Current: 2

During the past 13 years, the highest Piotroski F-Score of Medinet Co was 6. The lowest was 2. And the median was 3.

Medinet Co  (TSE:2370) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Medinet Co Piotroski F-Score Related Terms


Medinet Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Medinet Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medinet Co Piotroski F-Score Chart

Medinet Co Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 2.00 5.00 2.00

Medinet Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 2.00 0.00 0.00

TSE:2370 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Medinet Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medinet Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medinet Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Medinet Co's Piotroski F-Score falls into.


TSE:2370
41GF Score
Medinet Co Ltd TSE:2370
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep25) TTM:Last Year (Sep24) TTM:
Net Income was 円-1,362.1 Mil.
Cash Flow from Operations was 円-1,413.4 Mil.
Revenue was 円810.3 Mil.
Gross Profit was 円109.7 Mil.
Average Total Assets from the begining of this year (Sep24)
to the end of this year (Sep25) was (5700.031 + 4254.07) / 2 = 円4977.0505 Mil.
Total Assets at the begining of this year (Sep24) was 円5,700.0 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.0 Mil.
Total Current Assets was 円3,611.6 Mil.
Total Current Liabilities was 円233.1 Mil.
Net Income was 円-1,277.0 Mil.

Revenue was 円768.5 Mil.
Gross Profit was 円112.7 Mil.
Average Total Assets from the begining of last year (Sep23)
to the end of last year (Sep24) was (5634.145 + 5700.031) / 2 = 円5667.088 Mil.
Total Assets at the begining of last year (Sep23) was 円5,634.1 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.0 Mil.
Total Current Assets was 円5,013.1 Mil.
Total Current Liabilities was 円268.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Medinet Co's current Net Income (TTM) was -1,362.1. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Medinet Co's current Cash Flow from Operations (TTM) was -1,413.4. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep24)
=-1362.138/5700.031
=-0.23897028

ROA (Last Year)=Net Income/Total Assets (Sep23)
=-1276.994/5634.145
=-0.22665267

Medinet Co's return on assets of this year was -0.23897028. Medinet Co's return on assets of last year was -0.22665267. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Medinet Co's current Net Income (TTM) was -1,362.1. Medinet Co's current Cash Flow from Operations (TTM) was -1,413.4. ==> -1,413.4 <= -1,362.1 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep24 to Sep25
=0/4977.0505
=0

Gearing (Last Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/5667.088
=0

Medinet Co's gearing of this year was 0. Medinet Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep25)=Total Current Assets/Total Current Liabilities
=3611.617/233.11
=15.49318777

Current Ratio (Last Year: Sep24)=Total Current Assets/Total Current Liabilities
=5013.076/268.922
=18.64137557

Medinet Co's current ratio of this year was 15.49318777. Medinet Co's current ratio of last year was 18.64137557. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Medinet Co's number of shares in issue this year was 264.648. Medinet Co's number of shares in issue last year was 253.282. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=109.721/810.291
=0.13540938

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=112.692/768.501
=0.14663872

Medinet Co's gross margin of this year was 0.13540938. Medinet Co's gross margin of last year was 0.14663872. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep24)
=810.291/5700.031
=0.14215554

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep23)
=768.501/5634.145
=0.13640064

Medinet Co's asset turnover of this year was 0.14215554. Medinet Co's asset turnover of last year was 0.13640064. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Medinet Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
Medinet Co (TSE:2370) has a Piotroski F-Score of 2 as of Jul. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Medinet Co and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Medinet Co's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Medinet Co ranks #972 out of 1333 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Medinet Co's Piotroski F-Score too high?
Medinet Co's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Medinet Co's value of 2 is 33.3% below this industry median. Based on the distribution chart, Medinet Co ranks #972 out of 1333 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #972 out of 1333 companies for Piotroski F-Score. This places Medinet Co in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Medinet Co's value of 2 is 33.3% below this benchmark. Historically, Medinet Co's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Medinet Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinet Co's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Medinet Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinet Co's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.74, compared to a current price of 円25.00 — trading 40.1% below its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Piotroski F-Score is 2 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medinet Co (TSE:2370) Overvalued in 2026?

Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued. The current stock price of 円25.00 is trading 40.1% below its estimated GF Value™ of 円41.74. GuruFocus considers Medinet Co to be Possible Value Trap.

Key valuation signals for TSE:2370:

  • Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
  • GF Value™: 円41.74 vs. price of 円25.00 (40.1% below fair value)
  • GF Score™: 41/100 with 6 warning signs
  • Industry Position: 33.3% below the Biotechnology median (#972 of 1333)

No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medinet Co Business Description

Address 1-1 Heiwajima 6-chome, 9th Floor, TRC Center Building, Ota-ku, Yokohama, JPN, 143-0006
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score

Get the complete analysis for TSE:2370

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円25.00
Price
円41.74
GF Value